Regarding "Neuro-Oncology Practice Clinical Debate: Targeted Therapy Vs Conventional Chemotherapy in Pediatric Low-grade Glioma"
Overview
Overview
Journal
Neurooncol Pract
Publisher
Oxford University Press
Date
2020 Oct 5
PMID
33014399
Citations
2
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Modrzejewska M, Olejnik-Wojciechowska J, Roszyk A, Szychot E, Konczak T, Szemitko M J Clin Med. 2023; 12(21).
PMID: 37959175 PMC: 10649937. DOI: 10.3390/jcm12216709.
A new era for optic pathway glioma: A developmental brain tumor with life-long health consequences.
Walker D, Aquilina K, Spoudeas H, Pilotto C, Gan H, Meijer L Front Pediatr. 2023; 11:1038937.
PMID: 37033188 PMC: 10080591. DOI: 10.3389/fped.2023.1038937.
References
1.
Stokland T, Liu J, Ironside J, Ellison D, Taylor R, Robinson K
. A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). Neuro Oncol. 2010; 12(12):1257-68.
PMC: 3018938.
DOI: 10.1093/neuonc/noq092.
View
2.
Clifford C, Haynes B, Dobson V
. Are norms based on the original Teller Acuity Cards appropriate for use with the new Teller Acuity Cards II?. J AAPOS. 2005; 9(5):475-9.
DOI: 10.1016/j.jaapos.2005.04.011.
View
3.
Gnekow A, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B
. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012; 14(10):1265-84.
PMC: 3452343.
DOI: 10.1093/neuonc/nos202.
View
4.
Cooney T, Yeo K, Kline C, Prados M, Haas-Kogan D, Chi S
. Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract. 2020; 7(1):4-10.
PMC: 7104878.
DOI: 10.1093/nop/npz033.
View
5.
Azizi A, Walker D, Liu J, Sehested A, Jaspan T, Pemp B
. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2020; 23(1):100-111.
PMC: 7850076.
DOI: 10.1093/neuonc/noaa153.
View